M. Izquierdo

发表

Progress in the clinical development of new marine-derived anticancer compounds.

K. Rinehart, J. Jimeno, J. López-Martín, 2004, Anti-cancer drugs.

Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies.

C. Meijer, M. Flens, M. Izquierdo, 1994, Cancer research.

Tissue distribution of the multidrug resistance protein.

M. Flens, P. Groep, M. de Haas, 1996, The American journal of pathology.

HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.

S. Hilsenbeck, R. Schiff, J. Parker, 2019, Journal of the National Cancer Institute.

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

J. Pérez-Ruixo, A. Soto-Matos, M. Izquierdo, 2008, Cancer Chemotherapy and Pharmacology.

Male breast cancer. Report of a series of 50 cases.

M. Izquierdo, B. Ojeda, C. Alonso, 1994, Acta oncologica.

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group

H. Hollema, A. Boddy, D. Richel, 2007, Clinical Cancer Research.

Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors.

G. Giaccone, C. Meijer, M. Flens, 1996, The American journal of pathology.

Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues.

M. Flens, M. Izquierdo, G. Scheffer, 1998, The American journal of pathology.

Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer

E. Wiemer, M. Izquierdo, G. Scheffer, 2000, Current opinion in oncology.

Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material

I. Catalá, J. Schellens, M. Izquierdo, 2002, The Journal of pathology.

Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes

P. Greenberg, G. Garcia-Manero, M. Izquierdo, 2020, Annals of Internal Medicine.

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.

E. Eisenhauer, I. Vergote, G. Kristensen, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex

Sung-Bae Kim, C. Sotiriou, J. Huober, 2022, Journal for ImmunoTherapy of Cancer.

Ovarian carcinoma preceded by cerebral metastasis: review of the literature.

X. Matías-Guiu, M. Izquierdo, B. Ojeda, 1992, Gynecologic oncology.

CASE REPORT Ovarian Carcinoma Preceded by Cerebral Review of the Literature Metastasis

X. Matías-Guiu, M. Izquierdo, N. Ojeda, 1992 .

Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients

D. Richel, J. Schellens, J. Beijnen, 2007, Clinical pharmacokinetics.

Effects of the hematopoietic growth factors GM-CSF, IL-3, and IL-6 on human tumor colony-forming units taken directly from patients.

D. V. Von Hoff, M. Izquierdo, L. Myers, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study

James C Yao, Tetsuhide Ito, M. Izquierdo, 2019, OncoTargets and therapy.

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.

W. Gradishar, H. Iwata, S. Johnston, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells.

R. Shoemaker, M. Flens, M. Izquierdo, 2002, European journal of cancer.

Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42.

E. Moran, M. Clynes, M. Izquierdo, 1997, European journal of cancer.

Activity of the morpholino anthracycline 3′-deamino-3′-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming unitsin vitro

G. Clark, M. Izquierdo, D. D. Hoff, 2004, Investigational New Drugs.

Relationship of LRP-human major vault protein toin vitro and clinical resistance to anticancer drugs

L. Rome, R. Shoemaker, M. Flens, 2004, Cytotechnology.

Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin 3 fusion protein, on human tumor colony-forming units taken directly from patients.

Caron, E. Raymond, D. V. Von Hoff, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications.

G. Capellá, X. G. Del Muro, E. Condom, 2003, The Journal of urology.

The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.

M. Piccart, V. Torri, J. Baselga, 2018, European journal of cancer.

Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors

R. Salazar, J. Tabernero, L. Paz-Ares, 2008, Clinical Cancer Research.

Expression of Multidrug Resistance-Associated Markers, Their Relation to Quantitative Pathologic Tumour Characteristics and Prognosis in Advanced Ovarian Cancer

P. V. van Diest, J. Baak, P. Kenemans, 2002, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

M. Izquierdo, G. Scheffer, R. Scheper, 1998, Cytotechnology.

Transporter molecules in multidrug resistance

M. Flens, M. Izquierdo, G. Scheffer, 2004, Cytotechnology.

A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours.

R. Salazar, M. Izquierdo, R. Mesía, 2006, European journal of cancer.

Reports of Clinical Benefit of Plitidepsin (Aplidine), a New Marine-Derived Anticancer Agent, in Patients With Advanced Medullary Thyroid Carcinoma

E. Raymond, S. Faivre, J. López-Martín, 2009, American journal of clinical oncology.

Major vault protein LRP-related multidrug resistance.

M. Flens, M. Izquierdo, G. Scheffer, 1996, European journal of cancer.

The drug resistance-related protein LRP is the human major vault protein

H. Clevers, C. Meijer, M. Slovak, 1995, Nature Medicine.

Overlapping phenotypes of multidrug resistance among panels of human cancer‐cell lines

R. Shoemaker, M. Flens, M. Izquierdo, 1996, International journal of cancer.

Differential expression of the c‐kit proto‐oncogene in germ cell tumours

G. Giaccone, R. Ueda, Takashi Takahashi, 1995, The Journal of pathology.

A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer

B. Mellado, G. Scambia, J. Pérez-Gracia, 2004, International Journal of Gynecologic Cancer.

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial

M. Piccart, M. Iorio, J. Baselga, 2019, Clinical Cancer Research.

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

J. Blay, G. Demetri, M. von Mehren, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

C. Balañà, L. Paz-Ares, J. Bellmunt, 2012, Investigational New Drugs.

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy

M. Piccart, L. Pusztai, M. Iorio, 2020, International journal of molecular sciences.

STAT3 activation in HER2‐positive breast cancers: Analysis of data from a large prospective trial

C. Sotiriou, M. Piccart, Minetta C. Liu, 2020, International journal of cancer.

Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours

E. Condom, A. Zurita, M. Izquierdo, 2003, British Journal of Cancer.

Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma.

P. Sonneveld, J. Beliën, M. Izquierdo, 1998, Blood.

Identification of novel drug resistance–associated proteins by a panel of rat monoclonal antibodies

M. Flens, M. Izquierdo, A. Huysmans, 1997, International journal of cancer.

Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.

G. Giaccone, A. V. D. Van Der Zee, M. Flens, 1995, Journal of the National Cancer Institute.

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

R. Gelber, M. Piccart, J. Baselga, 2018, Journal of the National Cancer Institute.

Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines.

J. Neefjes, M. Flens, M. Izquierdo, 1996, British Journal of Cancer.

Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells

A. Monks, R. Shoemaker, C. Hose, 2002, British Journal of Cancer.

Unresectable nonmetastatic squamous cell carcinoma of the esophagus managed by sequential chemotherapy (cisplatin and bleomycin) and radiation therapy

M. Izquierdo, E. Marcuello, A. Gómez, 1993, Cancer.

Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2)

G. Arnaldi, Jacques Young, J. Bertherat, 2022, Pituitary.

Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension

M. Fleseriu, C. Scaroni, M. Roughton, 2022, European journal of endocrinology.

End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO

M. Iorio, H. Gómez, G. Pruneri, 2023, Frontiers in Oncology.

Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.

C. Bokemeyer, R. Hofheinz, C. Peschel, 2008, Lung cancer.

Malignant ovarian germ cell tumors: The experience at the Hospital de la Santa Creu i Sant Pau

M. Climent, M. Izquierdo, B. Ojeda, 1993, Gynecologic oncology.

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)

M. Piccart, L. Pusztai, Dar-Ren Chen, 2017, Breast Cancer Research and Treatment.

A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A + B study)

J. Friedberg, J. Zaucha, M. Izquierdo, 2021, British journal of haematology.

Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's Lymphoma

M. Izquierdo, M. Quinlan, J. Chandler, 2022, Clinical pharmacology in drug development.

A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy.

D. Maloney, M. Ogura, K. Tobinai, 2020, Blood advances.

An open‐label, multicenter, efficacy, and safety study of deferasirox in iron‐overloaded patients with non‐transfusion‐dependent thalassemia (THETIS): 5‐year results

M. Cappellini, V. Viprakasit, A. Taher, 2022, American journal of hematology.

Crushed deferasirox film‐coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single‐arm, interventional phase 4 study (MIMAS)

P. Charoenkwan, V. Viprakasit, M. Izquierdo, 2022, American journal of hematology.

Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab.

S. Loi, G. Pruneri, S. Michiels, 2022, Journal of the National Cancer Institute.

Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.

W. Gradishar, S. Johnston, S. Im, 2017 .

Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patients with Advanced Solid Tumors

J. Smyth, D. Jodrell, J. Jimeno, 2008, Clinical Cancer Research.

Phase IClinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patientswith Advanced SolidTumors

J. Smyth, D. Jodrell, M. Garci, 2008 .

Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis

C. Sotiriou, M. Piccart, M. Colombo, 2021, Clinical Cancer Research.

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial

M. Piccart, L. Harris, B. Naume, 2017, Journal of the National Cancer Institute.

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.

J. Baselga, B. Naume, C. Criscitiello, 2018, European journal of cancer.

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

R. Gelber, J. Baselga, Z. Aziz, 2021, European journal of cancer.

W. Gradishar, H. Iwata, S. Johnston, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.

J. Tabernero, L. Paz-Ares, V. Alfaro, 2007, Clinical colorectal cancer.

Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I)

A. Cesne, S. Schuetze, P. Casali, 2007 .

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.

R. Motzer, P. Russo, T. Choueiri, 2021, European urology.

Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC)

P. Kantoff, M. Michaelson, W. Oh, 2005 .

Sequential trials of cisplatin, vinblastine, and bleomycin and etoposide and cisplatin in disseminated nonseminomatous germ cell tumors of the testis with a good prognosis at a single institution

A. F. Sagarra, M. Izquierdo, J. Germà, 1993, Cancer.

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial

M. Piccart, M. Daidone, J. Huober, 2020, Breast cancer research : BCR.

A phase II trial of carboplatin in untreated patients with extensive stage small cell lung cancer

A. F. Sagarra, M. Izquierdo, C. Pallarés, 1991, Cancer.

Carboplatin for advanced bladder cancer.

M. Izquierdo, L. de Andrés, E. Marcuello, 1990, European journal of cancer.

Malignant ovarian Germ cell tumors : The experience at the Hospital de la Santa Creu i Sant Pau

M. Climent, M. Izquierdo, B. Ojeda, 1992 .

Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies

T. Ciuleanu, C. Sessa, N. Colombo, 2007 .

Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary results.

T. Ciuleanu, A. Poveda, M. Izquierdo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.